Cellular Reprogramming in Pursuit of Immortality  by Surani, M. Azim
Cell Stem Cell
ForumCellular Reprogramming in Pursuit of ImmortalityM. Azim Surani1,2,*
1Wellcome Trust Cancer Research UK Gurdon Institute
2Wellcome Trust Medical Research Council Stem Cell Institute
University of Cambridge, Cambridge CB2 1QN, UK
*Correspondence: a.surani@gurdon.cam.ac.uk
http://dx.doi.org/10.1016/j.stem.2012.11.014
The discovery that phenotypic diversity among differentiated cells results from epigenetic and not genetic
differences, and can be reset to restore pluripotency, promises revolutionary advances inmedicine. I discuss
how this and related seminal discoveries have brought us to an exciting future.Immortality comes in many forms. For
example, the creators of great works of
art that become ingrained in human con-
sciousness achieve immortality through
collective appreciation. John Gurdon
and Shinya Yamanaka, who received the
2012 Nobel Prize for Physiology or Medi-
cine for their groundbreaking work on
‘‘the discovery that mature cells can be
reprogrammed to become pluripotent,’’
have deservedly achieved immortality for
another reason—their research—and the
work they have been engaged in is
nothing less than an attempt to turn the
developmental clock back to the time
when we start our individual journeys
from a single cell.
Development is unidirectional; indi-
vidual cells do not return to the point
from where they start; instead they differ-
entiate to terminal states and then ulti-
mately succumb to aging and disease.
Throughout this complex process, cells
by and large retain the same genetic infor-
mation they had at the start. This state-
ment sounds so obvious now, but this
was not clear in 1962 when John Gurdon
published his findings (Gurdon, 1962)
and established the principle that cells
do not lose genetic information when
they differentiate. He showed that indi-
vidual cells can be reprogrammed back
to the point fromwhere they can recapitu-
late their developmental history. This
founding principle was important for the
inspired work of Yamanaka in 2006,
whose simple and elegant approach has
made it possible to convert any adult
mammalian cell into an induced pluripo-
tent stem cell (iPSC) (Takahashi and
Yamanaka, 2006), and has revolutionized
and accelerated research on stem cells in
a way that we could not have foreseen just
a few short years ago. The combined748 Cell Stem Cell 11, December 7, 2012 ª2endeavor in the field also seeks to explore
and answer fundamental questions in
biology, such as how cells acquire and
maintain their different states. If we can
understand this regulation, and as a result
manipulate cellular states experimentally,
we could unlock the potential to provide
great advances in human medicine.
Aldous Huxley’s 1932 science fiction
book Brave New World depicts a future
with human clones of different classes
occupying diverse societal niches in
a hierarchical order. Nearly 30 years later,
John Gurdon’s work on cloning in
Xenopus brought reality a little closer to
science fiction when he showed that,
when transplanted into a Xenopus egg
devoid of its own genetic material, a
differentiated intestinal cell nucleus can
acquire totipotency and develop into
a living individual. Using this approach,
it is possible to generate an endless
number of genetically identical animals.
This simple but elegant experiment is
notable because it clarified an issue that
others, including Briggs and King in early
1950s, were exploring, which was to
establish whether cells as they differen-
tiate retain the complete genetic infor-
mation they were endowed with at the
beginning.
It was clear at the time that this funda-
mental discovery in Xenopus should
in theory apply to mammals, so it is
surprising that despite strenuous efforts
by many groups, including that of Steen
Willadsen and Davor Solter, it took
another 35 years to move from theory to
reality. It was not until 1996 that we had
an unequivocal demonstration that the
same principle applies in mammals,
when Ian Wilmut, Keith Campbell, and
their colleagues showed with Dolly the
sheep that adult mammalian cells could012 Elsevier Inc.indeed be reprogrammed when trans-
planted into oocytes and acquire totipo-
tency (Campbell et al., 1996). Numerous
mammalian species such as pigs and
cows have now been cloned, including
and famously a ‘‘copy cat,’’ aptly called
Cc (for carbon copy). This work clearly
showed that cellular differentiation in-
volves epigenetic rather than genetic
modifications to generate the myriad of
differentiated cells that emerge from a
totipotent zygote. The term ‘‘epigenetic’’
has come into vogue more recently,
although Conrad Waddington used it
initially in 1954 in his famous and fre-
quently invoked ‘‘epigenetic landscape.’’
Importantly, epigenetic modifications,
unlike genetic changes, can be erased,
manipulated, and reinitiated, and logi-
cally, therefore, one cell type could be
converted to another cell type.
Why did it take so long to clone
a mammal? The difficulty was partly tech-
nical, owing to the necessity of microma-
nipulation of small and fragile mammalian
oocytes, but another important compo-
nent, as in all things to do with develop-
ment, was a matter of getting the timing
right. The study on cloned sheep provided
the much needed impetus to pursue
the mechanism of reprogramming, which
became the focus of intense interest and
activity especially after Yanagimachi
established cloning in the experimentally
more tractable mice in 1998, which
generated many new ideas through the
work of Jaenisch and others. Nonethe-
less, the mechanism of reprogramming
of somatic nuclei still remains to be fully
elucidated.
Cloning in mammals induced some
strong reactions, as it raised the pros-
pect of human cloning and, for some,
an opportunity to seek ‘‘immortality’’ for
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concerns, a nonbinding United Nations
Declaration called for the ban of all forms
of human cloning in 2005. So, is this the
end of the matter? There was a time,
unimaginable now, that the pursuit of
human in vitro fertilization (IVF) and IVF
babies, for which Robert Edward received
a Nobel Prize in 2010, was viewed with
intense hostility both by the public and
by some prominent scientists because of
concerns that the procedure could result
in the birth of deformed babies. Yet, since
the birth of Louise Brown, the first ‘‘test
tube baby’’ in 1978 (Steptoe and Ed-
wards, 1978), there are now 5 million IVF
babies worldwide. It is important to note
that the derivation of human pluripotent
stem cells was also helped by IVF, which
was the source of blastocysts used for
this work, and that IVF has also led to
the great advances in prenatal genetic
diagnosis. Recent work has also raised
the possibility of dealing with the devas-
tating consequences of inheritance of
defective mitochondria by using cloning
techniques to transplant pronuclei from
patients with defective zygotes into
normal enucleated donor oocytes with
normal mitochondria. A new program
along these lines funded by the Wellcome
Trust at Newcastle University may poten-
tially eradicate defective mitochondria
permanently from afflicted families.
Parallel but unrelated studies that were
crucial building blocks for this year’s
Nobel Prize had unexpected and unusual
origins. In the 1950s, Leroy Stevens found
that a certain mouse strain was prone
to development of enormous testicular
tumors, which consisted ofmany differen-
tiated somatic cell types (Stevens and
Little, 1954). He subsequently showed
that these testicular teratomas could orig-
inate from primordial germ cells (PGCs),
the precursors of sperm and eggs. These
studies eventually led to the identification
of embryonal carcinoma cells (ECCs) from
teratomas, with the demonstration that
a single ECC can form a teratoma; ECCs
can therefore be thought of as cancer
stem cells. Notably, like single cells of
the inner cell mass of blastocysts, an
ECC introduced into a host blastocyst
is capable of differentiating into many
diverse cell types, illustrating its pluripo-
tent character. Human ECCs were also
identified and were the subject of investi-
gations. Thus, significant discoveries canhave unexpected origins, and can be the
foundation of entire and important new
fields of research.
Despite the germ cell origin of at least
some apparently pluripotent ECCs,
ECCs themselves were never unequivo-
cally shown to give rise to germ cells.
However, the work on ECCs concen-
trated attention on important questions,
and helped to establish basic approaches
and culture conditions that became
critical for the quest toward alternative
ways of isolating pluripotent stem cells.
The work on ECCs in many ways set the
scene for what followed, which were
attempts to derive pluripotent stem cells
by another route.
The work of Martin Evans and Matt
Kaufmann in Cambridge, and Gail Martin
at UCSF in California, built on insights
from the ECC studies. These researchers
independently reported the derivation
of embryonic stem cells (ESCs) from
the inner cell mass of blastocysts in
1981(Evans and Kaufman, 1981; Martin,
1981). The cells they established showed
the properties of self-renewal and the
potential to differentiate into all cell types,
including germ cells. The transmission of
ESCs through the germline became the
focus of major attention because they
provided an important tool for gene
targeting, gene traps, and for generating
reporters, and thus for major advances
in mammalian developmental biology
and, ultimately, to the creation of mouse
models for human diseases. This advance
was recognized by the award of the Nobel
Prize to Capecchi, Evans, and Smithies
in 2007.
It took nearly 18 years after the estab-
lishment of mouse ESCs before James
Thomson first isolated and established
human pluripotent stem cells (Thomson
et al., 1998). While not absolutely iden-
tical, mouse and human ESCs are by
and large similar. The derivation of human
ESCs changed the perception of these
cells from being a tool for developmental
biologists to being cells with a huge
potential for advances in medicine,
because it became possible to imagine
that ESCs could be used to generate
any cell type for therapeutic purposes.
The work on the biology and properties
of ESCs themselves was being pursued
by relatively few scientists, notably and
particularly by Austin Smith. These
studies emerged from the backgroundCell Stem Cell 11,and moved to center stage, with
increasing efforts being directed toward
defining specific culture conditions, and
identifying transcription factors, such as
Oct4, Sox2, and Nanog, that are essential
for pluripotency.
The work on cloning and ESCs
occurred alongside other advances,
among which was the work of Hal
Weintraub and colleagues, who in 1987
demonstrated that expression of a single
transcription factor, MyoD, in fibroblasts
could elicit a program of myogenesis
and convert them into muscle cells (Davis
et al., 1987). Different cell types re-
sponded in this way to a greater or lesser
extent, and MyoD was dubbed a ‘‘master
regulator.’’ This demonstration estab-
lished the important principle that tran-
scription factors can force the conversion
of one cell type into another. Preceding
the work on MyoD was the demonstration
by Peter Jones that treatment of 10T1/2
cells with a DNA demethylating agent
called 5-azacytidine caused them to
differentiate into adipogenic, myogenic,
and chondrogenic cells. This experiment
suggested the importance of epigenetic
mechanisms in regulating cell fates, and
was important for the identification of
MyoD. The concept of transcription factor
master regulators was also taking hold
through the work of Walter Gehring, who
showed in 1995 that the mammalian
Pax6 gene, which specifies eye develop-
ment, could also induce eye development
in ectopic sites in Drosophila.
The pioneering work of Henry Harris in
1969 also provided important back-
ground to cellular reprogramming. Harris
showed that malignant cancer cells fused
to fibroblasts were no longer malignant
due to gene repression (Harris et al.,
1969). Helen Blau’s work in 1983–84
along similar lines showed that fusion of
cells with skeletal muscle cells activated
muscle gene expression in nonmuscle
cells, indicating the existence of transact-
ing factors capable of inducing transdif-
ferentiation. Takashi and Masako Tada
in 1997 in my lab and thereafter indepen-
dently in 2001 also showed that pluripo-
tent stem cells fused with somatic cells
could transform the latter into pluripotent
stem cells. This experiment showed that
ESCs contain trans-acting factors that
can convert somatic cells into pluripotent
stem cells without the need to transplant
somatic nuclei into oocytes.December 7, 2012 ª2012 Elsevier Inc. 749
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factors capable of converting somatic
cells to pluripotent stem cells was starting
to emerge. However, the low efficiency of
restoring totipotency to somatic nuclei
following transplantation into oocyte and
the poor understanding of the underlying
mechanism led to the notion that a large
number of factors, perhaps even over
100, might be needed to convert somatic
cells into pluripotent stem cells. The
differentiated cell state is also highly
stable and maintained by DNA meth-
ylation, an epigenetic modification that
is difficult to erase. Nevertheless,
Yamanaka took up this challenge, and in
a relatively short time was able to report
his groundbreaking achievement of in-
ducing pluripotency by introducing a
specific set of transcription factors (Taka-
hashi and Yamanaka, 2006). Other than
the sheer reliability of the approach, it
was also astonishing that only four
factors, Oct4, Sox2, Klf4, and c-Myc,
were needed to induce pluripotency in
somatic cells. Different factor combina-
tions and even noncoding RNAs have
since been reported to function in reprog-
ramming of mouse and human somatic
cells, but in most cases only a few factors
are required to induce the transformation.
This discovery, which has revolutionized
the field of reprogramming and stem cells,
has been adopted on a truly phenomenal
and industrial scale within a short space of
time. This pace of development is re-
flected by the awarding of the Nobel Prize
only 6 years after the publication of the
initial paper. Work on human induced
pluripotent stem cells (iPSCs) does not
suffer from the same ethical constraints
as research on human ESCs, which is
also often more time consuming and
requires precious human preimplantation
embryos. However, it will be important
for overall progress to continue research
on ESCs as well.
The work on iPSCs has many implica-
tions, including those for germ cell
biology, a subject that I personally have
a strong interest in. Germ cells are
sometimes called the ‘‘immortal’’ lineage
because they generate the totipotent
state in vivo and transmit genetic informa-
tion to all generations. Anne McLaren750 Cell Stem Cell 11, December 7, 2012 ª2considered germ cells to be the ‘‘most
fascinating and deeply mysterious cells’’
of them all. With her enthusiastic support,
we embarked on a quest to unravel the
mysteries of mammalian germ cells at
the Gurdon Institute 12 years ago with
Petra Hajkova, Mitinori Saitou, and
Katsuhiko Hayashi, among others. The
recent work by Hayashi and Saitou on
the derivation of sperm and oocytes
from mouse ESCs and iPSCs has raised
the possibility of breaking the ‘‘Weissman
Barrier’’ by transferring genetic informa-
tion from the soma to the germline
through the conversion of somatic cells
to gametes. The prospect of being able
to generate the totipotent state from adult
somatic cells in this way brings us close to
the concept of immortality.
There is little doubt that the ability to
generate iPSCs from somatic cells has
transformed the anticipated advances in
regenerative medicine, in ways that have
been articulated in numerous research
and review articles. Just to take one
example, the ability to generate iPSCs
from patients with specific diseases
or mutations has opened up prospects
for studying how such disease states
develop from the start, by following iPSCs
as they recapitulate all the steps toward
differentiation of affected tissues, and
how they function at a cellular level
through the analysis of differentiated
cells. These in vitro models for human
diseases can be used to screen for diag-
nostic and therapeutic agents, which by
itself is an advance of great magnitude
even if iPSCs do not ultimately fulfill all
of their envisaged promises as vehicles
for cell replacement therapy.
The importance of work on iPSCs and
nuclear transplantation for advances in
fundamental knowledge should also not
be underestimated. A deeper under-
standing of underlying mechanisms of
reprogramming could, and can, be used
for efficient and direct conversion of one
cell type into another, and such transdif-
ferentiation approaches bypass the need
to return to the pluripotent state. Such
an approach could even potentially be
used to induce changes in cell states
in vivo for recruitment of endogenous
stem cells, and for dealing with dis-012 Elsevier Inc.ease states. Advances in this field might
even make it possible to generate
synthetic cells with desirable diverse
properties that do not have direct in vivo
counterparts.
Biological research has undergone a
dramatic transformation in recent years,
with genome-scale approaches and
advances in systems biology becoming
particularly prominent. Rather than being
a pursuit undertaken by small groups or
even individuals, it is now a multi-
disciplinary, multigroup, and international
enterprise, and many of the current
approaches to funding are structured
around supporting this type of endeavor.
Looking back, however, it is evident that
transformational advances can start with
small steps by individuals that may seem
of little consequence except to those
who are driven simply by a desire to find
out how it all works. Inmy view, it is crucial
to provide support for individuals, some of
whommay well be future Nobel laureates,
who have an obsession to explore partic-
ular areas of research for their own sake.
What we can safely predict is that the
future is unpredictable, and that we can
look forward to many more currently
unknowable twists that underpin quantum
leaps in science.
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